<DOC>
	<DOCNO>NCT00571675</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multinational Phase 2 study evaluate compare oral AT-101 combination docetaxel prednisone versus docetaxel prednisone plus placebo treatment chemotherapy-naïve metastatic hormone-refractory prostate cancer , receive hormonal therapy chemotherapy .</brief_summary>
	<brief_title>A Study Comparing AT-101 Combination With Docetaxel Prednisone Versus Docetaxel Prednisone Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer ( HRPC )</brief_title>
	<detailed_description>Further Study Details provide Ascenta .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>1 . Males age ≥ 18 year histologically confirm adenocarcinoma prostate , metastatic ( e.g . T , N , M1ac ) base bone scan , CT scan , MRI scan . 2 . Progression disease despite androgen deprivation ( androgen ablation surgical castration ) antiandrogen withdrawal document one follow . Progression measurable disease per RECIST Bone scan progression , define appearance ≥ 2 new lesion bone scan , attributable prostate cancer Rising PSA , define increase level least two consecutive assessment , follow prior assessment take reference value , follow met : The assessment least one week apart , first assessment least one week later reference value Progressive increase two assessment reference value , without intervene decrease assessment . The last value prior study entry ≥ 2 ng/mL 3 . Serum testosterone level ≤ 50 ng/dL post orchiectomy maintain continuous intermittent medical androgen suppression LHRH agonist antagonist . 4 . At least 2 week since ketoconazole systemic steroid ( dose ) ; 2 week since prior flutamide , megestrol , aminoglutethimide ; least 2 week since prior bicalutamide nilutamide 5 . Radiation therapy and/or therapy samarium must complete 4 week prior first dose therapy . Strontium therapy must complete least 12 week prior first dose therapy . The patient must recover treatmentrelated toxicity . 6 . ECOG performance status ≤ 2 7 . Able swallow retain oral medication 1 . Received prior chemotherapy ( include estramustine phosphate [ Estracyt ] ) HRPC . Adjuvant chemotherapy ( include docetaxel ) allow provide progression disease occur ≥ 6 month completion adjuvant therapy . 2 . Patients must receive concurrent antiandrogen hormonal therapy HRPC ( LHRH direct therapy acceptable maintain castrate level testosterone ) . 3 . Treatment monoclonal antibody ( e.g. , VEGF target antibody ) prostate cancer vaccine within 45 day prior first dose study treatment . Acute toxicities prior therapy must resolve Grade ≤ 1 . 4 . Known history clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis 5 . Active secondary malignancy history malignancy within last 5 year 6 . Prior history radiation therapy ≥ 30 % bone marrow 7 . Peripheral neuropathy ≥ Grade 2 8 . Patients malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel exclude . Subjects ulcerative colitis , inflammatory bowel disease , partial complete small bowel obstruction also exclude . 9 . Class 3 4 cardiac disease define New York Heart Association Functional Classification 10 . Known active symptomatic fungal , bacterial and/or viral infection include active HIV . Note : screening virus require . 11 . Psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Metastatic ( Stage IV ) Disease</keyword>
	<keyword>Chemotherapy-naïve metastatic Hormone Refractory Prostate Cancer ( HRPC )</keyword>
</DOC>